Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.
|Articles|May 26, 2022
- May 2022
- Volume 88
- Issue 5
Pet Peeves: May 2022
Pet peeves are brought to you by The Sassy Pharmacist.
Advertisement
Ringing Off the Hook
Calling about home COVID-19 tests 100 times a day.
Mask of Least Resistance
Patients cutting the line to get free N95 masks.
Now You Tell Me
When a patient comes in to pick up a prescription or prescriptions and part way through checking them out say they have other prescriptions to pick up for other individuals.
What’s Bothering You?
Bossy patients, abandoned prescriptions, drive-through demands? We want to know! Send your pet peeves to cmollison@pharmacytimes.com. We’ll share them here and online.
Articles in this issue
over 4 years ago
Case Studies: May 2022over 4 years ago
Generic Product News: May 2022over 4 years ago
Rx Product News: May 2022over 4 years ago
OTC Cases: Stomach Infectionsover 4 years ago
Cibinqo From Pfizer Incover 4 years ago
Burnout: Self-care Is Not the Answerover 4 years ago
OTC Product News: May 2022over 4 years ago
Advancing Multistate Licensure Is Vital in Telehealth Eraover 4 years ago
Insomnia Is Hiding in Plain Sightover 4 years ago
Home-Based Services Improve Health OutcomesAdvertisement
Related to this article
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.
A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.
October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
3
Caitlin McClain, Peggy Lillis Foundation Board Member, Shares Her Experience With C difficile
4
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
5